Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer

Equality Impact Assessment (Guidance development) (PDF 236 KB)

Final appraisal determination

Final appraisal determination document (PDF 279 KB)

Committee papers ACM2 (PDF 1.6 MB)

Committee papers ACM3 (PDF 5.4 MB)

Committee papers ACM4 (PDF 1.25 MB)

Breast cancer (HER2 positive, metastatic) - pertuzumab (with trastuzumab and docetaxel): DSU spec - assessing technologies that are not cost effective at a zero price (PDF 68 KB)

Breast cancer (HER2 positive, metastatic) - pertuzumab (with trastuzumab and docetaxel): final matrix (PDF 32 KB)

Breast cancer (HER2 positive, metastatic) - pertuzumab (with trastuzumab and docetaxel): appraisal consultation

Breast cancer (HER2 positive, metastatic) - pertuzumab (with trastuzumab and docetaxel): appraisal consultation document information

Breast cancer (HER2 positive, metastatic) - pertuzumab (with trastuzumab and docetaxel): evaluation report (PDF 6.26 MB)

Breast cancer (HER2 positive, metastatic) - pertuzumab (with trastuzumab and docetaxel): final scope (PDF 52 KB)

Breast cancer (HER2 positive, metastatic) - pertuzumab (with trastuzumab and docetaxel): matrix - February 2013 (PDF 52 KB)

Breast cancer (HER2 positive, metastatic) - pertuzumab (with trastuzumab and docetaxel): response to consultee and commentator comments on the provisional matrix of consultees and commentators (PDF 158 KB)

Breast cancer (HER2 positive, metastatic) - pertuzumab (with trastuzumab and docetaxel): equalities impact assessment (PDF 30 KB)

Breast cancer (HER2 positive, metastatic) - pertuzumab (with trastuzumab and docetaxel): provisional matrix (pre-referral) - January 2012 (PDF 98 KB)

Breast cancer (HER2 positive, metastatic) - pertuzumab (with trastuzumab and docetaxel): draft scope for consultation (pre-referral) - January 2012 (PDF 102 KB)